Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Treasury Shares (2019 - 2025)

C4 Therapeutics (CCCC) has 6 years of Treasury Shares data on record, last reported at $2.9 million in Q3 2025.

  • For Q3 2025, Treasury Shares rose 43183.48% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, up 43183.48%, while the annual FY2024 figure was $98000.0, 36.36% down from the prior year.
  • Treasury Shares reached $2.9 million in Q3 2025 per CCCC's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.0 million in Q2 2025 and bottomed at $6634.0 in Q3 2024.
  • Average Treasury Shares over 4 years is $889118.3, with a median of $563500.0 recorded in 2022.
  • Peak YoY movement for Treasury Shares: tumbled 99.12% in 2024, then skyrocketed 43183.48% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $468316.0 in 2022, then crashed by 67.12% to $154000.0 in 2023, then plummeted by 36.36% to $98000.0 in 2024, then soared by 2830.03% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.9 million in Q3 2025, $3.0 million in Q2 2025, and $98000.0 in Q4 2024.